Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer are needed for a study to research an immunotherapy drug

IRB/UVA Tracking #
20535
Principal Investigator
Linda R Duska
Contact
Benjamin Prabhu
Contact Email
Contact Phone
434.297.4980
Official Trial Title
A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ov
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for women ages 18 and over who have ovarian cancer, fallopian tube cancer or primary peritoneal cancer which has grown or has recurred. The purpose of this study is to learn more about the effects of adding an immunotherapy drug (Atezolizumab) to the usual chemotherapy (liposomal doxorubicin and/or bevacizumab) and to learn if adding immunotherapy is more effective than chemotherapy alone.

Your participation will continue as long as the treatment is helping you. The follow-up after treatment could last up to 5 years. The immunotherapy drug will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02839707

Compensation

N/A